Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Surfactants Clear all
Completed Not applicable Interventional Results available

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

NCT02834624
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Poractant alfa, calfactant
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
22 Weeks to 35 Weeks
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Jul 22, 2026, 2:17 AM EDT
Not listed Phase 4 Interventional

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

NCT02140580
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Minimally invasive surfactant therapy, Continuation on CPAP
Device · Other
Lead sponsor
Menzies Institute for Medical Research
Other
Eligibility
1 Minute to 6 Hours
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Honolulu, Hawaii • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 2Phase 3 Interventional

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

NCT01203358
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions
Exosurf, Survanta
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 6 Hours
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1992
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Jul 22, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Jul 22, 2026, 2:17 AM EDT
No Longer Available No phase listed Expanded access

Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

NCT03582930
View directory record Official record
Conditions
Neonatal Respiratory Distress
Interventions
Infasurf Aero
Combination Product
Lead sponsor
ONY
Industry
Eligibility
Up to 42 Weeks
U.S. locations
5
States / cities
Jackson, Mississippi • Buffalo, New York • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial

NCT02907593
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD)
Interventions
Budesonide in Calfactant
Drug
Lead sponsor
Cynthia McEvoy
Other
Eligibility
3 Days to 14 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 22, 2026, 2:17 AM EDT
Completed No phase listed Observational

The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis

NCT03531996
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jul 22, 2026, 2:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology of Surfactant Protein-B Deficiency

NCT00014859
View directory record Official record
Conditions
Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant, Lung Diseases, Interstitial
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 1 Year
Enrollment
5,176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Jul 22, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 22, 2026, 2:17 AM EDT
Terminated Not applicable Interventional

Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)

NCT00599651
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Surfactant administered via Laryngeal Mask Airway (LMA), standard of care (nasal CPAP and supplemental oxygen)
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 72 Hours
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

NCT04662151
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
AT-100, Air-sham
Biological · Procedure
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
0 Minutes to 96 Hours
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 22, 2026, 2:17 AM EDT
Terminated Phase 3 Interventional Results available

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

NCT02772081
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS)
Interventions
LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
Combination Product · Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
30 Minutes to 24 Hours
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 22, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

NCT06776783
View directory record Official record
Conditions
Respiratory Distress Syndrome, Pre-term Infants
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
Combination Product · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Little Rock, Arkansas • La Jolla, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04

NCT03748173
View directory record Official record
Conditions
Bronchiolitis
Interventions
Aerosolized Infasurf
Combination Product
Lead sponsor
ONY
Industry
Eligibility
0 Months to 4 Months
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

NCT00233324
View directory record Official record
Conditions
Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Interventions
Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%
Drug · Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Weeks to 27 Weeks
Enrollment
1,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 22, 2026, 2:17 AM EDT
Recruiting No phase listed Observational

A National Registry For Pulmonary Alveolar Proteinosis

NCT02461615
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome

NCT00244101
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
PS Group, NCPAP Group, ISX Group
Drug · Device
Lead sponsor
Vermont Oxford Network
Network
Eligibility
26 Weeks to 29 Weeks
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 22, 2026, 2:17 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Little Lungs Study

NCT06855043
View directory record Official record
Conditions
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Interventions
Calfactant, Budesonide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Days to 14 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Recruiting Not applicable Interventional

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

NCT06446453
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants, Intensive Care Units, Neonatal
Interventions
Echography-guided Surfactant THERapy (ESTHER)
Diagnostic Test
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
0 Hours to 2 Hours
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

NCT01042600
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal tube insertion, Laryngeal mask airway insertion
Device
Lead sponsor
Albany Medical College
Other
Eligibility
4 Hours to 48 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jul 22, 2026, 2:17 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prophylactic Minimally Invasive Surfactant Evaluation

NCT06007547
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Premature Birth
Interventions
Poractant Alfa
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 15 Minutes
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 22, 2026, 2:17 AM EDT
Not listed Phase 2 Interventional

Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.

NCT01268215
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Infasurf, Pulmicort, Sham
Drug · Other
Lead sponsor
East Carolina University
Other
Eligibility
24 Weeks to 28 Weeks
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Jul 22, 2026, 2:17 AM EDT
Terminated Phase 3 Interventional

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

NCT00005774
View directory record Official record
Conditions
Infant, Newborn, Respiratory Distress Syndrome, Respiratory Insufficiency
Interventions
Early surfactant, Standard practice
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 12 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 22, 2026, 2:17 AM EDT